Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis.
Conclusions: These findings suggested that omalizumab had beneficial effects on moderate-to-severe asthma in children. Patients may benefit more from long-term use of omalizumab. In addition, omalizumab reduces the rate of serious adverse events requiring hospitalizations.
PMID: 32602383 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
More News: Asthma | Children | Corticosteroid Therapy | Pediatrics | Respiratory Medicine | Study | Xolair